timothy sykes logo

Stock News

Is TG Therapeutics Capitalizing on Recent Growth to Soar Higher?

Timothy SykesAvatar
Written by Timothy Sykes Reviewed by Jack Kellog Fact-checked by Ellis Hobb
Is TG Therapeutics Capitalizing on Recent Growth to Soar Higher? Thumbnail

Positive momentum for TG Therapeutics Inc.’s stock is likely bolstered by recent news of their $4 million collaboration with the NIH for the development of ublituximab. On Wednesday, TG Therapeutics Inc.’s stocks have been trading up by 12.46 percent.

Key Updates and Developments

  • H.C. Wainwright has increased its price target for TG Therapeutics to $55 and holds a Buy rating, citing strong Q3 revenue growth and optimistic scales for Briumvi.

Candlestick Chart

Live Update at 17:03:11 EST: On Wednesday, November 13, 2024 TG Therapeutics Inc. stock [NASDAQ: TGTX] is trending up by 12.46%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

  • Following a high-volume survey, B. Riley adjusted the price target to $38, reflecting an encouraging outlook for Briumvi and anticipating its potential market entry.

  • TG Therapeutics revised its U.S. revenue target for BRIUMVI up to $300M-$305M reflecting increased confidence in its commercial performance.

  • Ladenburg sees promise with Briumvi, raising the price target from $43 to $45, underpinned by strong earnings.

  • Despite some equity weakness due to changes in reporting metrics, sequential growth bolsters optimism for Briumvi’s future market performance.

TG Therapeutics Financial Overview

TG Therapeutics recently reported robust financial outcomes for the third quarter of 2024. With revenue soaring, the U.S. BRIUMVI net sales, their flagship product for multiple sclerosis treatment, saw record highs. Consequently, the company increased its full-year revenue projections. The quarter’s highlights include clinical breakthroughs, new trials, regulatory nods for innovative drug applications, and the addition of a second U.S. manufacturing partner.

The stock’s prices echoed these positive stories. The data reveals a steady climb with a notable consolidation above $30. This resilience suggests investor confidence fueled by clinical milestones and revenue growth. Despite a slight missed expectation on EPS, the beat on revenue has compensated by showcasing promising sales and clinical advancements. The impressive list of achievements has fortified the stock’s position, shifting investor focus from past metrics to future potentials.

Financially dissecting the stock, TG Therapeutics’ gross margin boasts a high percentage, highlighting efficient production cost management. However, profitability ratios exhibit negatives due to its ongoing investment in growth and R&D, a characteristic typical for biopharma in active expansion phases. Long-term debt levels are adequately leveraged against robust cash reserves, securing operational liquidity to support strategic ventures.

More Breaking News

Despite inherent challenges, the improved current and quick ratios underscore the firm’s capability to cover short-term liabilities, buttressed by significant cash absorption from continuous financing efforts. Its projected growth in revenue per share holds promise given its recent financial uplift, though investors should weigh market risks inherent in the biopharmaceutical sector.

Deciphering Impactful Market News

The latest surge in TG Therapeutics’ stock is intricately linked to the positive data emerging during its third-quarter earnings report. The increase in BRIUMVI’s sales figures has not just buoyed immediate financial expectations but has also invigorated long-term investor sentiment. The announcement of heightened revenue forecasts introduces a narrative of stability and optimism around TG Therapeutics’ market position.

Further bolstering this outlook is the feedback from recent medical surveys and analysts. The revised price targets from key financial institutions indicate a consensus regarding the value proposition TG Therapeutics offers amidst its peers. Anticipation regarding BRIUMVI’s upcoming market entries fuels speculation of amplified revenue streams, cementing the stock’s appeal despite sector-wide volatilities.

The stock’s performance trajectory finds additional underpinnings in its consistent quarterly growth pattern. This methodical scaling of financial benchmarks indicates that the company is aligning its strategic roadmap with market expectations. Furthermore, TG Therapeutics’ dynamic approach towards diversifying its operational base enhances the robustness of its financial ecosystem.

Conclusion: Analyzing the Path Forward for TG Therapeutics

TG Therapeutics embodies a tale of cautious optimism, progressively stitching together elements of strategic expansion, financial prudence, and market adaptability. The positive momentum seen in recent quarters is indicative of another chapter in its fledgling rise.

While analysts’ price targets paint a rosy picture, the real test will lie in sustaining this trajectory as the biopharmaceutical landscape evolves. As they amplify clinical pipelines and strive towards market consolidation, the investment narrative of TG Therapeutics will appeal to those with an eye for burgeoning market opportunities balanced against timely caution.

For enthusiasts and stakeholders alike eager to navigate the ebb and flow of market dynamics, TG Therapeutics represents a case of promising potential buoyed by tangible performance indicators. The stakes are well defined, with future forecasts hinging on the realization of strategic goals and broader market acceptability of their groundbreaking therapies.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Our traders will never trade any stock until they see a setup they like. Their strategy is to capture short-term momentum while avoiding undue risk exposure to a stock’s long-term volatility. This method is especially useful when trading penny stocks or other high-risk equities, where rapid gains can be made by understanding stock patterns, manipulation, and media hype. Whether you are an active day trader looking for key indicators on a stock’s next move, or an investor doing due diligence before entering a position, Timothy Sykes News is designed to help you make informed trading decisions.

Curious about this stock and eager to learn more? Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success. Start your journey towards financial growth and trading mastery!

But wait, there’s more! Elevate your trading game with StocksToTrade, the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade harnesses the power of Artificial Intelligence to guide you through the market’s twists and turns. Discover insights on Robinhood penny stocks and top biotech picks to fuel your trading journey:

Ready to embark on your financial adventure? Click the links and let the journey unfold.

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply
Author card Timothy Sykes picture

Timothy Sykes

Tim Sykes is a penny stock trader and teacher who became a self-made millionaire by the age of 22 by trading $12,415 of bar mitzvah money. After becoming disenchanted with the hedge fund world, he established the Tim Sykes Trading Challenge to teach aspiring traders how to follow his trading strategies. He’s been featured in a variety of media outlets including CNN, Larry King, Steve Harvey, Forbes, Men’s Journal, and more. He’s also an active philanthropist and environmental activist, a co-founder of Karmagawa, and has donated millions of dollars to charity. Read More

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”